Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
about
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyondPrimary and acquired resistance to biologic therapies in gastrointestinal cancers.Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.Current therapeutic landscape for advanced gastroesophageal cancers.Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.Next generation sequencing-based emerging trends in molecular biology of gastric cancer.Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.New therapeutic options opened by the molecular classification of gastric cancer.
P2860
Q26744088-40737979-0D6A-4E66-B31D-57CACF652066Q28078788-6E833A42-132D-4DE6-9981-565E4EDE4317Q33895573-1BD59195-614B-4CD6-8195-7771F333FF26Q47100522-4DD2D7F9-9F50-46C1-80E3-52EDF6656B6DQ47425148-148DA8C0-D1DA-4D33-9128-CBBDD21E80EBQ48327644-0C8F61F1-234D-458D-9309-C3FADBE58141Q50642054-448225D7-C2E3-4EA4-852E-805B899981EFQ52581752-1AC4BFBC-CAD9-40CD-9F14-19CCCDC5AF5BQ54109361-66208A39-4D4B-4C33-8C68-2B87955470EFQ54261019-377A59E6-2209-4885-8AA5-28533B928422Q55240690-6DF51D7C-13F3-47BF-87B8-AD02EE55CF87Q55527185-42641058-D7C0-4A0E-9118-03B0D0BC9A96
P2860
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@ast
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@en
type
label
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@ast
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@en
prefLabel
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@ast
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@en
P2093
P2860
P1433
P1476
Optimal regimen of trastuzumab ...... a multicenter, phase II trial.
@en
P2093
Jifang Gong
Jinwan Wang
Liwei Wang
Qingxia Fan
Shukui Qin
Tianshu Liu
P2860
P2888
P356
10.1186/S12885-016-2092-9
P407
P577
2015-01-01T00:00:00Z
P5875
P6179
1013426971